University of Hertfordshire


  • Elisa Vergari
  • Jakob G Knudsen
  • Reshma Ramracheya
  • Albert Salehi
  • Quan Zhang
  • Julie Adam
  • Ingrid Wernstedt Asterholm
  • Anna Benrick
  • Linford J B Briant
  • Margarita V Chibalina
  • Fiona M Gribble
  • Alexander Hamilton
  • Benoit Hastoy
  • Frank Reimann
  • Nils J G Rorsman
  • Ioannis I Spiliotis
  • Andrei Tarasov
  • Yanling Wu
  • Frances M Ashcroft
  • Patrik Rorsman
View graph of relations
Original languageEnglish
Article number139
Number of pages1
Pages (from-to)139
JournalNature Communications
Journal publication date11 Jan 2019
Publication statusPublished - 11 Jan 2019


Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose production. This counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism mediated by stimulation of intra-islet somatostatin release. Insulin's capacity to inhibit glucagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of these compounds in vivo antagonises insulin's hypoglycaemic effect. We extend these data to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered as adjuncts to insulin in diabetes therapy.


© The Author(s) 2019

ID: 16120242